Short review – Management of Immune Thrombocytopenia in adults
- 50 Downloads
In recent years clinical management of Immune Thrombocytopenia (ITP) has clearly changed due to the emergence of new therapeutics such as Thrombopoietin Receptor Agonists or Rituximab. These agents have been tested in phase III randomized controlled trials and thereby initiated an impulse for the whole field of ITP. Moreover, in 2009 various publications systematically reviewed current practice, presented efforts of standardization as well as new guidelines for diagnosis and treatment of ITP. This short review is intended to summarize these new developments and to propose an up-dated treatment algorithm.
KeywordsIdiopathic Thrombocytopenic Purpura Immune Thrombocytopenia ITP Therapy Management
Unable to display preview. Download preview PDF.
- Arnold DM, Bernotas A, Nazi I, Stasi R, Kuwana M, Kelton JG, et al. The efficacy of H. pylori eradication therapy in H. pylori-infected and uninfected patients with immune thrombocytopenic purpura: a systematic review. Blood, 112(11): 1170, 2008Google Scholar
- Zaja F, Baccarani M, Mazza P, Vianelli N, Bocchia M, Gugliotta L, et al. A prospective randomized study comparing rituximab and dexamethasone vs dexamethasone alone in ITP: results of final analysis and long term follow up. Blood, 112(11): 3, 2008Google Scholar
- Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet, 373(9664): 641–648, 2009CrossRefPubMedGoogle Scholar